Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere

Hypertrophic cardiomyopathy is the second most common cause of cardiomyopathy presenting during childhood and whilst its underlying aetiology is variable, the majority of disease is caused by sarcomeric protein gene variants. Sarcomeric disease can present at any age with highly variable disease phe...

Full description

Bibliographic Details
Main Authors: Gabrielle Norrish, Ella Field, Juan P. Kaski
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2021.708679/full
id doaj-d011ab1f07044d7baa2a907ff9acaa73
record_format Article
spelling doaj-d011ab1f07044d7baa2a907ff9acaa732021-07-02T06:56:18ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602021-07-01910.3389/fped.2021.708679708679Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac SarcomereGabrielle Norrish0Gabrielle Norrish1Ella Field2Ella Field3Juan P. Kaski4Juan P. Kaski5Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United KingdomInstitute of Cardiovascular Sciences University College London, London, United KingdomCentre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United KingdomInstitute of Cardiovascular Sciences University College London, London, United KingdomCentre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United KingdomInstitute of Cardiovascular Sciences University College London, London, United KingdomHypertrophic cardiomyopathy is the second most common cause of cardiomyopathy presenting during childhood and whilst its underlying aetiology is variable, the majority of disease is caused by sarcomeric protein gene variants. Sarcomeric disease can present at any age with highly variable disease phenotype, progression and outcomes. The majority have good childhood-outcomes with reported 5-year survival rates above 80%. However, childhood onset disease is associated with considerable life-long morbidity and mortality, including a higher SCD rate during childhood than seen in adults. Management is currently focused on relieving symptoms and preventing disease-related complications, but the possibility of future disease-modifying therapies offers an exciting opportunity to modulate disease expression and outcomes in these young patients.https://www.frontiersin.org/articles/10.3389/fped.2021.708679/fullpaediatrichypertrophic cardiomyopathysarcomeresudden deathprogression
collection DOAJ
language English
format Article
sources DOAJ
author Gabrielle Norrish
Gabrielle Norrish
Ella Field
Ella Field
Juan P. Kaski
Juan P. Kaski
spellingShingle Gabrielle Norrish
Gabrielle Norrish
Ella Field
Ella Field
Juan P. Kaski
Juan P. Kaski
Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere
Frontiers in Pediatrics
paediatric
hypertrophic cardiomyopathy
sarcomere
sudden death
progression
author_facet Gabrielle Norrish
Gabrielle Norrish
Ella Field
Ella Field
Juan P. Kaski
Juan P. Kaski
author_sort Gabrielle Norrish
title Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere
title_short Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere
title_full Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere
title_fullStr Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere
title_full_unstemmed Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere
title_sort childhood hypertrophic cardiomyopathy: a disease of the cardiac sarcomere
publisher Frontiers Media S.A.
series Frontiers in Pediatrics
issn 2296-2360
publishDate 2021-07-01
description Hypertrophic cardiomyopathy is the second most common cause of cardiomyopathy presenting during childhood and whilst its underlying aetiology is variable, the majority of disease is caused by sarcomeric protein gene variants. Sarcomeric disease can present at any age with highly variable disease phenotype, progression and outcomes. The majority have good childhood-outcomes with reported 5-year survival rates above 80%. However, childhood onset disease is associated with considerable life-long morbidity and mortality, including a higher SCD rate during childhood than seen in adults. Management is currently focused on relieving symptoms and preventing disease-related complications, but the possibility of future disease-modifying therapies offers an exciting opportunity to modulate disease expression and outcomes in these young patients.
topic paediatric
hypertrophic cardiomyopathy
sarcomere
sudden death
progression
url https://www.frontiersin.org/articles/10.3389/fped.2021.708679/full
work_keys_str_mv AT gabriellenorrish childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere
AT gabriellenorrish childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere
AT ellafield childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere
AT ellafield childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere
AT juanpkaski childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere
AT juanpkaski childhoodhypertrophiccardiomyopathyadiseaseofthecardiacsarcomere
_version_ 1721336742102958080